PRESS RELEASES

Date Title and Summary View
Toggle Summary Company Profile for Galectin Therapeutics Inc.
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug (GR-MD-02) is a carbohydrate drug that inhibits the galectin-3 protein that is directly involved in multiple inflammatory, fibrotic, and
View HTML
Toggle Summary Galectin Therapeutics Inc. Announces New CEO
NORCROSS, Ga. , June 12, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold H. Shlevin , Ph.D., currently the Company’s Chief Operating Officer (COO), has been appointed Chief Executive
View HTML
Toggle Summary Galectin Therapeutics Inc. Announces Richard E. Uihlein Elected Chairman of the Board
NORCROSS, Ga. , June 04, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that the directors elected Richard E. Uihlein as Chairman of the Board of Directors. Additionally, Kevin D.
View HTML
Toggle Summary Galectin Therapeutics Proceeds to Phase 3 Development of GR-MD-02 for NASH Cirrhosis Following FDA Meeting
NORCROSS, Ga. , May 14, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today it is proceeding with plans for a Phase 3 clinical trial program with its galectin-3 inhibitor GR-MD-02 in NASH cirrhosis,
View HTML
Toggle Summary Galectin Therapeutics Reports 2018 First Quarter Financial Results and Provides Business Update
NORCROSS, Ga. , May 11, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for the three months ended March 31, 2018 , and provided a business update.
View HTML
Toggle Summary Galectin Therapeutics to Present at 2nd Annual NASH Summit 2018
NORCROSS, Ga. , April 18, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber , M.D., the Company’s CEO and CMO, has been selected as an expert speaker and will participate in
View HTML
Toggle Summary Galectin Therapeutics Late-Breaker Presentation at The International Liver Congress Reinforces and Extends the Positive Effects of GR-MD-02 in Patients With NASH Cirrhosis
NORCROSS, Ga. , April 16, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today provided highlights from a late-breaker oral presentation at The International Liver Congress™  2018 , European Association for the
View HTML
Toggle Summary Galectin Therapeutics to Present Late-Breaker Oral Presentation at The International Liver Congress 2018
GR-MD-02 treatment in NASH cirrhosis patients without esophageal varices shows statistically significant and clinically meaningful effects NORCROSS, Ga. , April 04, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. ( NASDAQ:GALT ) , the leading developer of therapeutics that target galectin
View HTML
Toggle Summary Galectin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
NORCROSS, Ga. , April 02, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.   (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber , M.D., the Company’s CEO and CMO, will present at the H.C.
View HTML
Toggle Summary Galectin Therapeutics Reports 2017 Financial Results and Provides Business Update
NORCROSS, Ga. , March 29, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for the year ended December 31, 2017 . These results are included in the Company's Annual Report on Form
View HTML